JP2025000642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025000642A5 JP2025000642A5 JP2024152809A JP2024152809A JP2025000642A5 JP 2025000642 A5 JP2025000642 A5 JP 2025000642A5 JP 2024152809 A JP2024152809 A JP 2024152809A JP 2024152809 A JP2024152809 A JP 2024152809A JP 2025000642 A5 JP2025000642 A5 JP 2025000642A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- amino acid
- binding fragment
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323285P | 2016-04-15 | 2016-04-15 | |
| US62/323,285 | 2016-04-15 | ||
| US201762442802P | 2017-01-05 | 2017-01-05 | |
| US62/442,802 | 2017-01-05 | ||
| US201762450438P | 2017-01-25 | 2017-01-25 | |
| US62/450,438 | 2017-01-25 | ||
| US201762460428P | 2017-02-17 | 2017-02-17 | |
| US62/460,428 | 2017-02-17 | ||
| PCT/US2017/027650 WO2017181021A1 (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| JP2019505138A JP2019515027A (ja) | 2016-04-15 | 2017-04-14 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2022108815A JP2022153418A (ja) | 2016-04-15 | 2022-07-06 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022108815A Division JP2022153418A (ja) | 2016-04-15 | 2022-07-06 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025000642A JP2025000642A (ja) | 2025-01-07 |
| JP2025000642A5 true JP2025000642A5 (https=) | 2025-03-05 |
Family
ID=60041925
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505138A Pending JP2019515027A (ja) | 2016-04-15 | 2017-04-14 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2022108815A Pending JP2022153418A (ja) | 2016-04-15 | 2022-07-06 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2024152809A Pending JP2025000642A (ja) | 2016-04-15 | 2024-09-05 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505138A Pending JP2019515027A (ja) | 2016-04-15 | 2017-04-14 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2022108815A Pending JP2022153418A (ja) | 2016-04-15 | 2022-07-06 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20190127455A1 (https=) |
| EP (1) | EP3442577A4 (https=) |
| JP (3) | JP2019515027A (https=) |
| KR (2) | KR20240005973A (https=) |
| AU (2) | AU2017250797A1 (https=) |
| CA (1) | CA3019665A1 (https=) |
| IL (1) | IL262277A (https=) |
| SG (2) | SG10202008378UA (https=) |
| WO (1) | WO2017181021A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| SG11201808426XA (en) | 2016-04-15 | 2018-10-30 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| EP3687464A4 (en) * | 2017-09-27 | 2021-09-29 | REGENXBIO Inc. | TREATMENT OF EYE DISEASES WITH A TOTALLY HUMAN POST-TRANSLATION MODIFIED ANTI-VEGF FAB |
| EP3727468A4 (en) * | 2017-12-19 | 2021-09-22 | Akouos, Inc. | AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| US12558434B2 (en) | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| BR112020025268A2 (pt) * | 2018-06-28 | 2021-03-09 | The University Of North Carolina At Chapel Hill | Cassetes de expressão e genes cln5 otimizados e seu uso |
| EP4063510A1 (en) * | 2018-11-07 | 2022-09-28 | Akouos, Inc. | Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear |
| WO2020206098A1 (en) * | 2019-04-03 | 2020-10-08 | Regenxbio Inc. | Gene therapy for eye pathologies |
| WO2020219868A1 (en) * | 2019-04-24 | 2020-10-29 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| EP4017523A4 (en) * | 2019-08-22 | 2024-01-17 | The Regents Of The University Of California | UBE3A FOR THE TREATMENT OF ANGELMAN SYNDROME |
| CN114502197A (zh) * | 2019-08-26 | 2022-05-13 | 再生生物股份有限公司 | 用全人经翻译后修饰的抗VEGF Fab治疗糖尿病性视网膜病变 |
| WO2021071835A1 (en) | 2019-10-07 | 2021-04-15 | Regenxbio Inc. | Adeno-associated virus vector pharmaceutical composition and methods |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN113952474A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| CA3198368A1 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Formulations for suprachoroidal administration such as formulations with aggregate formation |
| CA3198372A1 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Formulations for suprachoroidal administration such as high viscosity formulations |
| KR20230106598A (ko) | 2020-10-07 | 2023-07-13 | 리젠엑스바이오 인크. | 겔 제형과 같은 맥락막위 투여용 제형 |
| AU2021358781A1 (en) | 2020-10-07 | 2023-05-18 | Tern Therapeutics, Llc | Gene therapy for ocular manifestations of cln2 disease |
| CA3195967A1 (en) * | 2020-10-28 | 2022-05-05 | Xu Wang | Vectorized anti-tnf-? antibodies for ocular indications |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| CN116917491A (zh) * | 2020-12-18 | 2023-10-20 | Ac免疫有限公司 | 抗体递送 |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| JP2024513205A (ja) * | 2021-03-31 | 2024-03-22 | ウーシー バイオロジクス アイルランド リミテッド | 二重特異性抗ｐｄ－ｌ１／ｖｅｇｆ抗体およびその使用 |
| CA3245921A1 (en) * | 2022-03-17 | 2023-09-21 | Adverum Biotechnologies, Inc. | Antibody Cassettes of Constituent 3 Anti-Complement, Vectorization and Therapeutic Application |
| TW202345913A (zh) | 2022-04-06 | 2023-12-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如凝膠調配物 |
| US20260034243A1 (en) | 2022-04-06 | 2026-02-05 | Regenxbio Inc. | Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene for suprachoroidal administration |
| TW202404651A (zh) | 2022-04-06 | 2024-02-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如形成聚集體之調配物 |
| IL319873A (en) | 2022-09-30 | 2025-05-01 | Regenxbio Inc | Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0014945A (pt) * | 1999-10-21 | 2004-08-31 | Monsanto Co | Modificação pós-traducional de proteìnas recombinantes produzidas em plantas |
| CN1461342A (zh) * | 2000-07-26 | 2003-12-10 | 路德维格癌症研究所 | 糖基化vegf－b和增加可溶性vegf－b量的方法 |
| EP2443150B1 (en) * | 2009-06-17 | 2015-01-21 | AbbVie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| US20130090375A1 (en) * | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
| TWI698240B (zh) * | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| ES2833230T3 (es) * | 2014-05-13 | 2021-06-14 | Univ Pennsylvania | Composiciones que comprenden AVV que expresan construcciones y usos de doble anticuerpo del mismo |
-
2017
- 2017-04-14 KR KR1020237043995A patent/KR20240005973A/ko active Pending
- 2017-04-14 AU AU2017250797A patent/AU2017250797A1/en not_active Abandoned
- 2017-04-14 US US16/093,363 patent/US20190127455A1/en not_active Abandoned
- 2017-04-14 SG SG10202008378UA patent/SG10202008378UA/en unknown
- 2017-04-14 CA CA3019665A patent/CA3019665A1/en active Pending
- 2017-04-14 SG SG11201808440YA patent/SG11201808440YA/en unknown
- 2017-04-14 JP JP2019505138A patent/JP2019515027A/ja active Pending
- 2017-04-14 KR KR1020187032191A patent/KR20190003556A/ko not_active Ceased
- 2017-04-14 EP EP17783242.5A patent/EP3442577A4/en active Pending
- 2017-04-14 WO PCT/US2017/027650 patent/WO2017181021A1/en not_active Ceased
-
2018
- 2018-10-10 IL IL262277A patent/IL262277A/en unknown
-
2019
- 2019-03-22 US US16/361,884 patent/US20190211091A1/en not_active Abandoned
-
2022
- 2022-03-25 US US17/704,170 patent/US20230057519A1/en not_active Abandoned
- 2022-07-06 JP JP2022108815A patent/JP2022153418A/ja active Pending
-
2024
- 2024-08-09 AU AU2024205641A patent/AU2024205641A1/en active Pending
- 2024-09-05 JP JP2024152809A patent/JP2025000642A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025000642A5 (https=) | ||
| JP2022153418A5 (https=) | ||
| JP2022521851A5 (https=) | ||
| JP2025121920A (ja) | 完全ヒト翻訳後修飾抗体による治療剤 | |
| JP2021503914A5 (https=) | ||
| JP2024016207A5 (https=) | ||
| CN117467025B (zh) | 一种抗vegf和补体双功能融合蛋白及其应用 | |
| JP2022545967A5 (https=) | ||
| RU2018142768A (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| JP2021516671A5 (https=) | ||
| JP2022523679A (ja) | 体液性免疫を回避する組成物および方法 | |
| EP4549459A1 (en) | Aav drug for treating angiogenesis-related fundus diseases | |
| JP2022522776A5 (https=) | ||
| JP7842082B2 (ja) | 眼疾患を処置するための組成物および方法 | |
| JP2023545229A5 (https=) | ||
| CN116444626A (zh) | 经过修饰的aav衣壳蛋白及其用途 | |
| CN110423281A (zh) | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 | |
| JP2024520815A5 (https=) | ||
| JP2023547832A (ja) | 眼の適応症に対するベクター化抗ＴＮＦ－α抗体 | |
| WO2023215806A2 (en) | Vectorized anti-complement antibodies and complement agents and administration thereof | |
| WO2022092326A1 (ja) | 眼組織線維化の阻害に使用するためのｇｄｆ１５調節物質 | |
| US20240269327A1 (en) | Compositions and methods for transgene expression | |
| US20240279324A1 (en) | Multispecific antagonists | |
| CN121368636A (zh) | 干性年龄相关性黄斑变性的治疗 | |
| TW202417633A (zh) | 用於眼適應症之載體化抗TNF-α抑制劑 |